Methylene blue improves the hepatopulmonary syndrome

Area of Science:

• Cardiology
• Pulmonology
• Hepatology

Background:

• Hepatopulmonary syndrome (HPS) in severe chronic liver dysfunction causes hypoxemia due to pulmonary vasodilation.
• Currently, no established drug therapies exist for HPS.

Purpose of the Study:

• To investigate the efficacy of methylene blue, a guanylate cyclase inhibitor, in treating severe HPS.
• To assess the impact of methylene blue on gas exchange and hemodynamic parameters in HPS patients.

Main Methods:

• An open, uncontrolled trial was conducted in a medical intensive care unit.
• Seven patients with advanced cirrhosis and severe HPS (PaO2 ≤ 60 mm Hg) received intravenous methylene blue (3 mg/kg).
• Pulmonary artery and arterial catheters were used for serial measurements of gas exchange and hemodynamics.

Main Results:

• Methylene blue significantly increased PaO2 (from 58 to 74 mm Hg) and reduced the alveolar-arterial oxygen difference.
• Shunt fraction decreased from 41% to 25%, indicating improved oxygenation.
• Pulmonary artery pressure and vascular resistance increased, while cardiac output decreased, suggesting a shift from hyperdynamic circulation.

Conclusions:

• Intravenous methylene blue effectively improved hypoxemia in patients with severe HPS.
• Methylene blue also helped normalize the hyperdynamic circulatory state associated with HPS.